A user-friendly approach to drug delivery device development
Cutting-edge design that puts the patient first is at the heart of a new drug delivery device for multiple sclerosis (MS) sufferers. Product design and development firm Cambridge Consultants has worked with leading pharmaceutical company Novartis and medical device manufacturer Owen Mumford – plus hundreds of MS patients – to come up with the ExtaviPro® 30G auto-injector.
From its attractive visual design and ergonomic shape to its easy-to-read adjustable needle depth control, the ExtaviPro 30G has been designed with the needs of the patient in mind. More than 500 MS patients and healthcare professionals in the US, the UK and mainland Europe were involved in the development process to ensure the device was underpinned by a deep understanding of the users.
An estimated 2.5 million people worldwide have MS – a disease affecting the central nervous system. Symptoms can include vision problems, tingling and tremors, dizziness, balance problems, restricted mobility, fatigue and cognitive issues. The ExtaviPro 30G is aimed at people who suffer from relapsing forms of MS – such as clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) – who make up the majority of MS patients. They have periods when symptoms flare up aggressively, known as relapses, followed by periods of recovery – or remission. They often have to self-inject prescription medication at home to help reduce the impact and frequency of relapses.
“Our aim was to make the ExtaviPro 30G auto-injector very simple and intuitive to use, and enable one-handed injection,” said Andy Pidgeon, head of the industrial design and human factors group at Cambridge Consultants. “Its ergonomic shape leads patients to instinctively hold it correctly – which is vital for those who suffer from tremors, as having a firm grip is key to self-injecting safely.
“Another key factor was the feedback we received during our extensive user research. Patients wanted a soft, non-threatening design, for example – so we’ve made it very user friendly. And it’s led to the creation of a drug delivery device that doesn’t look like a badge of infirmity.”
As well as the look and feel of the auto-injector, Cambridge Consultants also developed the accompanying instruction leaflets – ensuring they were clear for MS sufferers with cognitive problems – as well as the travel bag for carrying the device and supplies for injections. To ensure the design truly reflected the needs and desires of patients, even the bag went through several rounds of user studies to ensure it best suited individual lifestyles.
The ExtaviPro 30G auto-injector has been launched in Europe – initially in Germany.
Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 850 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications. For more information, visit: www.cambridgeconsultants.com
Cambridge Consultants is part of Altran. Altran is the undisputed world leader in engineering and R&D services. The Group offers its customers a unique value proposition to meet their transformation and innovation challenges. Altran supports its customers, from concept to industrialization, to develop the products and services of tomorrow. Altran has been working for more than 35 years with major players in many sectors: Automotive, Aeronautics, Space, Defense & Naval, Rail, Infrastructure & Transport, Industry & Consumer Products, Life Sciences, Communications, Semiconductor & Electronics, Software & Internet, Finance & Public Sector. In 2019, Capgemini, and Altran announced a merger project in the context of a friendly tender offer to create a global leader in “Intelligent Industry”. Altran generated €3.2 billion in revenue in 2019, with more than 50,000 employees in more than 30 countries. www.altran.com